Cloning and pharmacological characterization of the equine adenosine A3 receptor.

This research focused on developing a system for expressing the equine adenosine A(3) receptor (eA(3)-R), in order to examine its pharmacological properties. The results indicated that the eA(3)-R functions in a similar way to other mammalian A(3) receptors, suggesting it could play a role in treating inflammation in horses.

Developing an Expression System for eA(3)-R

• The main objective of this study was to create a heterologous expression system, a tool that allows for the study of a protein or gene function in an unrelated host organism, for the eA(3)-R. This was done to understand it’s pharmacologic profile i.e., how it responds to different drugs.
• The eA(3)-R was expressed in human embryonic kidney cells (HEK), a commonly used cell line in molecular biology. The successful expression of these receptors was identified through radioligand binding assays. These assays involve using radioactive substances, here [(125)I]AB-MECA, to study molecular interactions.

Functional Coupling and Binding Assays

• Following successful expression, adenylate cyclase assays were used to demonstrate that the eA(3)-R was functionally coupled to the G-protein/adenylate cyclase system. This confirmed that the receptor was not only expressed but was functional in the cell environment.
• Next, equilibrium competition binding assays were performed to determine how effectively different agents could bind to the eA(3)-R. These assays compare the binding affinities of different ligands (molecules that bind to the receptor). The rank order of agonist potency was determined to be IB-MECA > NECA > CGS21680, and antagonist potency to be MRS1220 > ZM241385 > 8-p-sulphophenyltheophylline.

Inhibitory Effect and Potential Use

• The last part of the study looked at the effects of the receptor’s activation on a key pathway involved in inflammation. The assays revealed that activation of the eA(3)-R inhibited the activity of NF-kappaB, a protein complex involved in the inflammatory response, in a concentration-dependent manner.
• The results from this study indicate that the eA(3)-R not only performs similarly to other mammalian A(3) receptors, but its activation also has an inhibitory effect on key pathways in inflammation. Therefore, this receptor has potential to serve as a target in pharmacological interventions for treating inflammatory diseases in horses.